ICVX Overzicht aandelen
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Icosavax, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$15.31 |
| 52 Week Hoogtepunt | US$16.11 |
| 52 Week Laag | US$4.75 |
| Bèta | 1.28 |
| 11 maand verandering | -0.78% |
| 3 maanden verandering | 50.84% |
| 1 Jaar Verandering | 68.80% |
| 33 jaar verandering | n/a |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | -56.22% |
Recent nieuws en updates
Recent updates
We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth
Jul 04
Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?
Mar 10Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?
Oct 18Icosavax GAAP EPS of -$0.57
Aug 15Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones
Jul 28Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation
Jun 22Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation
Mar 24We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely
Oct 29Rendement voor aandeelhouders
| ICVX | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -0.6% | -0.7% | -1.6% |
| 1Y | 68.8% | 19.8% | 30.8% |
Rendement versus industrie: ICVX exceeded the US Biotechs industry which returned 4.8% over the past year.
Rendement versus markt: ICVX exceeded the US Market which returned 20.5% over the past year.
Prijsvolatiliteit
| ICVX volatility | |
|---|---|
| ICVX Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: ICVX's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: ICVX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2017 | 60 | Adam Simpson | icosavax.com |
Icosavax, Inc. Samenvatting
| ICVX fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$777.79m |
| Inkomsten(TTM) | -US$96.71m |
| Inkomsten(TTM) | n/a |
0.0x
P/S-verhouding-8.0x
Koers/WinstverhoudingIs ICVX overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ICVX resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$0 |
| Kosten van inkomsten | US$70.04m |
| Brutowinst | -US$70.04m |
| Overige uitgaven | US$26.67m |
| Inkomsten | -US$96.71m |
Laatst gerapporteerde inkomsten
Sep 30, 2023
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -1.90 |
| Brutomarge | 0.00% |
| Nettowinstmarge | 0.00% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde ICVX op de lange termijn?
Bekijk historische prestaties en vergelijking